To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®

Inclusion Criteria: * An adult female between the ages of 20 and 39 at the time of screening * Patients whose mean menstrual cycle was between 25 and 35 days * Patients whose FSH (follicle stimulating hormone) concentration does not exceed 13 mIU / mL at screening * Patients diagnosed with infertility due to one or more of the following A. Trouble Factors B. Male Factors C. Unexplained D. Uterine factors * Patients with previous IVF experience less than 3 * Patient who signed the written consent after hearing the explanation of the purpose, method and effect of the clinical trial Exclusion Criteria: * If the sperm donor (spouse or non-spouse) is a severe male factor (Non obstructive azoospermia) * Patients who were diagnosed as PCOS (polycystic ovary syndrome) during screening * Patient with abnormal uterine bleeding during screening * Patients diagnosed with primary ovarian failure * Patients who has ovarian cysts that are not related to PCOS during screening * Patients with tubal hydrops * Patients with untreated non-reproductive endocrine disease * Patients with a deformity of the reproductive organs that can not be conceived, or fibroids of the uterus that can not be conceived (only for submucosal myoma) * Patients with less than 2 ovaries (0 or1) * Patients with ovarian, breast, uterus, hypothalamus, or pituitary malignancies * Patients with BMI \<18 or BMI\> 30 * Patients with an LH concentration of less than 1.2mIU / mL during screening * Poor ovarian responder by bologna criteria * Patients with moderate or severe renal impairment (creatinine clearance \<60 mL / min) or liver function impairment (ALT or AST,\> 5 times normal) * Patients who experienced Grade 4 or higher OHSS (ovarian hyperstimulation syndrome) before * Patients who are contraindicated for pregnancy * Patients being pregnant or lactating * Patients with hypersensitivity to IP * Patients who have participated in other medication-related clinical trials since enrollment in this study, or have participated in other clinical trials within 3 months (90 days) before enrolling in this trial